Vittorio Perduca

Vittorio Perduca

Auto-generated profile, based on publicly available information

Vittorio Perduca

Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, 94805, Villejuif, France; Université Paris Cité, CNRS, MAP5, F-75006 Paris, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NPNikos Papadimitriou
Nikos Papadimitriou
NDNiki Dimou
Niki Dimou
KTKostas Tsilidis
Kostas Tsilidis
BBBarbara Banbury
Barbara Banbury
RMRichard M. Martin
Richard M. Martin
NMNeil Murphy
Neil Murphy
Physical activity has been associated with lower risks of breast and colorectal cancer in epidemiological studies; however, it is unknown if these associations are causal or confounded. In two-sample Mendelian randomisation analyses, using summary genetic data from the UK Biobank and GWA consortia, we found that a one standard deviation increment in average acceleration was associated with lower risks of breast cancer (odds ratio [OR]: 0.51, 95% confidence interval [CI]: 0.27 to 0.98, P-value = 0.04) and colorectal cancer (OR: 0.66, 95% CI: 0.48 to 0.90, P-value = 0.01). We found similar magnitude inverse associations for estrogen positive (ER+ve) breast cancer and for colon cancer. Our results support a potentially causal relationship between higher physical activity levels and lower risks of breast cancer and colorectal cancer. Based on these data, the promotion of physical activity is probably an effective strategy in the primary prevention of these commonly diagnosed cancers.

3 December 2018 in Nature Genetics
Verified
Journal Article
Open access
JHJeroen R. Huyghe
Jeroen R. Huyghe
SBStephanie A. Bien
Stephanie A. Bien
THTabitha A. Harrison
Tabitha A. Harrison
HKHyun Min Kang
Hyun Min Kang
SCSai Chen
Sai Chen
UPUlrike Peters
Ulrike Peters
To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genome-wide association study data, and tested for association in 34,869 cases and 29,051 controls. Findings were followed up in an additional 23,262 cases and 38,296 controls. We discovered a strongly protective 0.3% frequency variant signal at CHD1. In a combined meta-analysis of 125,478 individuals, we identified 40 new independent signals at P < 5 × 10-8, bringing the number of known independent signals for CRC to ~100. New signals implicate lower-frequency variants, Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling, long noncoding RNAs and somatic drivers, and support a role for immune function. Heritability analyses suggest that CRC risk is highly polygenic, and larger, more comprehensive studies enabling rare variant analysis will improve understanding of biology underlying this risk and influence personalized screening strategies and drug development.

1 April 2020 in Gastroenterology
Verified
Journal Article
Open access
PDF file
NMNeil Murphy
Neil Murphy
RCRobert Car-To
Robert Car-To
MSMingyang Song
Mingyang Song
ACAndrew T. Chan
Andrew T. Chan
RMRichard M. Martin
Richard M. Martin
MGMarc J. Gunter
Marc J. Gunter
Background & Aims Human studies examining associations between circulating levels of insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) and colorectal cancer risk have reported inconsistent results. We conducted complementary serologic and Mendelian randomization (MR) analyses to determine whether alterations in circulating levels of IGF1 or IGFBP3 are associated with colorectal cancer development. Methods Serum levels of IGF1 were measured in blood samples collected from 397,380 participants from the UK Biobank, from 2006 through 2010. Incident cancer cases and cancer cases recorded first in death certificates were identified through linkage to national cancer and death registries. Complete follow-up was available through March 31, 2016. For the MR analyses, we identified genetic variants associated with circulating levels of IGF1 and IGFBP3. The association of these genetic variants with colorectal cancer was examined with 2-sample MR methods using genome-wide association study consortia data (52,865 cases with colorectal cancer and 46,287 individuals without [controls]) Results After a median follow-up period of 7.1 years, 2665 cases of colorectal cancer were recorded. In a multivariable-adjusted model, circulating level of IGF1 associated with colorectal cancer risk (hazard ratio per 1 standard deviation increment of IGF1, 1.11; 95% confidence interval [CI] 1.05–1.17). Similar associations were found by sex, follow-up time, and tumor subsite. In the MR analyses, a 1 standard deviation increment in IGF1 level, predicted based on genetic factors, was associated with a higher risk of colorectal cancer risk (odds ratio 1.08; 95% CI 1.03–1.12; P = 3.3 × 10–4). Level of IGFBP3, predicted based on genetic factors, was associated with colorectal cancer risk (odds ratio per 1 standard deviation increment, 1.12; 95% CI 1.06–1.18; P = 4.2 × 10–5). Colorectal cancer risk was associated with only 1 variant in the IGFBP3 gene region (rs11977526), which also associated with anthropometric traits and circulating level of IGF2. Conclusions In an analysis of blood samples from almost 400,000 participants in the UK Biobank, we found an association between circulating level of IGF1 and colorectal cancer. Using genetic data from 52,865 cases with colorectal cancer and 46,287 controls, a higher level of IGF1, determined by genetic factors, was associated with colorectal cancer. Further studies are needed to determine how this signaling pathway might contribute to colorectal carcinogenesis.

10 December 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CDCatherine Dong
Catherine Dong
MMMarie Metzger
Marie Metzger
EHEinar Holsbø
Einar Holsbø
VPVittorio Perduca
Vittorio Perduca
FCFranck Carbonnel
Franck Carbonnel
Summary: Background: Acute severe ulcerative colitis (ASUC) is a life‐threatening condition. Mortality in ASUC decreased in published series but there is uncertainty as to whether this also applies to the real‐life setting.Aim: To perform a systematic review and meta‐analysis of mortality in ASUC in studies from referral centres and in population‐based studies, separately and combined. A second aim was to identify risk factors of mortality in ASUC.Methods: We searched pubmed and embase from 1998 to 2016, to identify studies that reported 3‐month or 12‐month mortalities of acute UC in adult patients treated in referral centres, and in population‐based studies.Results: Six population‐based studies with 741 743 patients and 47 referral centre‐based studies with 2556 patients were included. The pooled 3‐month and 12‐month mortalities were respectively 0.84% and 1.01%. Advanced age was significantly associated with both 3 month and 12 month mortalities (OR = 1.15 per year, 95% CI: 1.10‐1.20 and OR = 1.19 per year, 95% CI: 1.15‐1.23 respectively). The pooled 3‐month and 12‐month mortalities were 0.78% and 0.85% in studies with median age of less than 50 and 2.81% and 4.17% in studies with median age of 50 or more, respectively. After adjustment for age, 3‐month and 12‐month mortalities did not differ between population‐based and referral centre‐based studies.Conclusions: Mortality in acute severe ulcerative colitis is approximately 1%; it is higher in older patients. Efforts should be made to improve the care of elderly patients with severe UC.

25 August 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ACAntoine Chupin
Antoine Chupin
VPVittorio Perduca
Vittorio Perduca
AMAntoine Meyer
Antoine Meyer
CBChristophe Bellanger
Christophe Bellanger
FCFranck Carbonnel
Franck Carbonnel
CDCatherine Dong
Catherine Dong

15 November 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GSGhislaine Scelo
Ghislaine Scelo
DMDavid Muller
David Muller
ERElio Riboli
Elio Riboli
MJMattias Johansson
Mattias Johansson
ACAmanda J. Cross
Amanda J. Cross
RBRupal S. Bhatt
Rupal S. Bhatt
Purpose: Renal cell carcinoma (RCC) has the potential for cure with surgery when diagnosed at an early stage. Kidney injury molecule-1 (KIM-1) has been shown to be elevated in the plasma of RCC patients. We aimed to test whether plasma KIM-1 could represent a means of detecting RCC prior to clinical diagnosis. Experimental Design: KIM-1 concentrations were measured in prediagnostic plasma from 190 RCC cases and 190 controls nested within a population-based prospective cohort study. Cases had entered the cohort up to 5 years before diagnosis, and controls were matched on cases for date of birth, date at blood donation, sex, and country. We applied conditional logistic regression and flexible parametric survival models to evaluate the association between plasma KIM-1 concentrations and RCC risk and survival. Results: The incidence rate ratio (IRR) of RCC for a doubling in KIM-1 concentration was 1.71 [95% confidence interval (CI), 1.44–2.03, P = 4.1 × 10−23], corresponding to an IRR of 63.3 (95% CI, 16.2–246.9) comparing the 80th to the 20th percentiles of the KIM-1 distribution in this sample. Compared with a risk model including known risk factors of RCC (age, sex, country, body mass index, and tobacco smoking status), a risk model additionally including KIM-1 substantially improved discrimination between cases and controls (area under the receiver-operating characteristic curve of 0.8 compared with 0.7). High plasma KIM-1 concentrations were also associated with poorer survival (P = 0.0053). Conclusions: Plasma KIM-1 concentrations could predict RCC incidence up to 5 years prior to diagnosis and were associated with poorer survival. Clin Cancer Res; 24(22); 5594–601. ©2018 AACR.